Matthew D. Zimmerman

This study reevaluates PaBQU and DBQU regimens in mouse models, finding they have lesional liability in complex lesions, which may explain their failure in a human trial.

This study compares delamanid and pretomanid, finding similar bactericidal activity but pretomanid more effectively inhibits M. tuberculosis ribosomal rRNA synthesis.

This study evaluates replacing linezolid with spectinamide MBX-4888A in the Nix-TB regimen for tuberculosis in a mouse model, showing potential for reduced adverse effects.

The paper develops an orally effective biotin inhibitor, C48, against Mycobacterium tuberculosis, demonstrating in vivo efficacy in a low-biotin mouse model.

Rabbit lesion microdissection and pharmacokinetic modeling show bedaquiline takes months to reach deep caseum and years to clear, while TBAJ-587 and TBAJ-876 shorten these windows.

This study identifies a candidate transmission survival genome of Mycobacterium tuberculosis by exposing it to model aerosol fluid and analyzing gene contributions to survival during transmission.

This study investigates the physiologic recovery of Mycobacterium tuberculosis in mice after antibiotic treatment, finding that recovery is slow, sequential, and incomplete, with longer treatment leading to slower recovery.

This study identifies in vivo chemical-genetic interactions in tuberculosis that reveal novel drug targets and mechanisms, showing differences from in vitro results and highlighting metabolic dependencies affecting drug efficacy.

The paper develops a hybrid modeling pipeline to identify antitubercular compounds with favorable potency and pharmacokinetics, resulting in 12 promising candidates from a large compound library.

This study shows that MBX-4888A, a spectinamide, shortens tuberculosis treatment in murine models by improving tissue distribution and working well with rifampin and pyrazinamide.